News
The Spanish State at the forefront of Europe in young waterpipe tobacco smokers
A study in which IDIBELL and ICO professionals have participated confirms that 90% of electronic cigarette smokers also consume conventional cigarettes and warns that social networks are becoming a channel of promotion, covertly or indirectly, of tobacco products banned by the European Tobacco Products Directive (TPD).
New diagnostic biomarkers and new therapeutic targets for the minority disease Lymphangioleiomyomatosis
A study by IDIBELL and the ICO, with the collaboration of the Spanish LAM Association, has detected that patients suffering from Lymphangioleiomyomatosis have elevated plasma levels of a histamine derivative, which could be used for the diagnosis of the disease.
Dr. Sebastiano Biondo obtains the position of Professor of Surgery at the University of Barcelona
Dr. Sebastiano Biondo, head of the Digestive Tube Pathology research group at IDIBELL and the Bellvitge University Hospital, has obtained the position of Professor of Surgery at the University of Barcelona in the competition held on July 20.
Pancreatic beta-cell boost in mice paves way for future diabetes treatments
A research team from IDIBELL, CRG and UB has uncovered the role of a gene that is critical to boosting the number of insulin-producing cells during the early development of the pancreas. The findings could bolster diabetes research efforts and eventually lead to new replacement therapies for the disease.
Identified two new genes implicated in developmental brain diseases
Two studies with the participation of IDIBELL and the University of Barcelona have identified mutations in the CLCN3 gene, encoding a chloride transporter in endosomes, and the CHRM1 gene, corresponding to the M1 muscarinic neuronal receptor, as responsible for defects in brain development.
New advances in the characterization of the minority disease Limfangioleiomyomatosis
A team from IDIBELL and the ICO, through gene and protein expression analysis of the disease, has determined the biological traits that would explain the high heterogeneity and molecular similarities with cancer.
IDIBELL’s Innovation Unit receives the UNE 166002:2014 certification
The certification corroborates the conformity of the innovation management system according to the UNE 166002:2014 standard and certifies that IDIBELL is able to generate and manage innovation projects, systematize R+D+I activities and ensure that they are carried out effectively and efficiently.